Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation

Taylor and Francis Group, Expert Opinion on Biological Therapy, 7(18), p. 727-735, 2018

Journal article published in 2018 by Marco Galluzzo

, Sara Tambone, Giacomo Caldarola, Maria Concetta Fargnoli, Ketty Peris, Luca Bianchi

Distributing this paper is prohibited by the publisher

Full text: Unavailable

Preprint: archiving forbidden

Postprint: archiving restricted

Upload

Published version: archiving forbidden

Policy details

Data provided by